Scarica l'app Stockscreener
11.18
0.00%
0.00
Dopo l'orario di chiusura:
11.18
Precedente Chiudi:
$11.18
Aprire:
$11.18
Volume 24 ore:
1,113
Relative Volume:
33.00
Capitalizzazione di mercato:
$N/A
Reddito:
$614.00K
Utile/perdita netta:
$-76.35M
Rapporto P/E:
-0.1292
EPS:
-86.53
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
+6.86%
1M Prestazione:
-56.83%
6M Prestazione:
-76.92%
1 anno Prestazione:
+245.37%
Intervallo 1D:
$11.15
$11.37
Intervallo di 1 settimana:
$11.15
$11.37
Portata 52W:
$11.15
$11.37
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Nome
Finch Therapeutics Group Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta FNCH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| FNCH | 11.18 | 0 | 614.00K | -76.35M | -31.51M | -86.53 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | BofA Securities | Buy |
| 2021-04-13 | Iniziato | Evercore ISI | Outperform |
| 2021-04-13 | Iniziato | Jefferies | Buy |
Finch Therapeutics Group Inc Borsa (FNCH) Ultime notizie
Microbiome Therapeutics Market Set to Surge at 28.2% CAGR, to Reach USD 2455.7 Million by 2032 | VMR - News Channel Nebraska
Ulcerative Colitis Clinical Trials and Pipeline 2024: FDA - openPR
US Oil Fund (USO-A) QuotePress Release - The Globe and Mail
Human Microbiome Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and Forecast - The Globe and Mail
Microbiome Therapeutics Market to Hit $2.78 Billion by 2032, Fueled by Immune Disease Solutions - EIN News
Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 0.8% – Should You Buy? - Defense World
Acreage (OTCMKTS:ACRHF) Shares Down 15.6% – Should You Sell? - Defense World
MyMD Pharmaceuticals (NASDAQ:MYMD) Stock Price Up 2.4% – Time to Buy? - Defense World
S&P 500 Health Care [Sector] (SRHC) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Microbiome Therapeutics Whitespace Analysis Reveals Market Opportunities | Second Genome, Inc., Vedanta - EIN News
Microbiome Therapeutics Market Size, Analytical Overview, - openPR
Rtx Corp (RTX-N) QuotePress Release - The Globe and Mail
Finch Therapeutics to delist from Nasdaq by end of October - Investing.com Australia
Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire
PensionPro, Finch Partner to Automate the Collection of Critical Plan Sponsor Information - Yahoo Finance
Head to Head Analysis: AGNC Investment (NASDAQ:AGNCO) & Orchid Island Capital (NYSE:ORC) - Defense World
Silver Storm Mining Ltd (SVRS-X) QuotePress Release - The Globe and Mail
5 Best Microbiome Companies (November 2024) - Securities.io
Rivian Automotive’s (RIVN) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Commonwealth Equity Services LLC Buys 482 Shares of Urban Outfitters, Inc. (NASDAQ:URBN) - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.7% - Defense World
Microbiome Therapeutics Market to Receive Overwhelming Hike in Revenues by 2031 - Newstrail
Docusign Inc (DOCU-Q) QuotePress Release - The Globe and Mail
Human Microbiome Market Advancements Highlighted by Size, Trends, Opportunities,Segmentation Overview By 2031 - WhaTech
Forward Therapeutics Welcomes Ulrich Thienel, M.D., Ph.D. as Chief Medical Officer - PR Newswire
Human Microbiome Market Projected to Surpass to $3 Billion by 2032 with DuPont, Evelo Bio, Finch Therapeutics, Ginkgo Bioworks, Seres Therapeutics, AOBiome, Astarte Medical, Axial Biotherapeutics - Yahoo Finance UK
Litigator of the Week Runners-Up and Shout-Outs - Law.com
Ferring v Finch: Ripples From The DecisionPatentIntellectual PropertyUnited States - Mondaq News Alerts
Human Microbiome Market Projected to Surpass to $3 Billion by 2032 with DuPont, Evelo Bio, Finch - Daily Guardian Canada
Human Microbiome Market Projected to Surpass to $3 Billion - GlobeNewswire
Finch Wins $25 Million From Ferring on Fecal-Transplant Patents - Bloomberg Law
Delaware Jury Says Fecal Treatment Patents Are Worth $25M - Law360
Finch wins US jury trial against Ferring over fecal-transplant patents - Reuters
Finch Therapeutics Group (NASDAQ:FNCH) & OKYO Pharma (NASDAQ:OKYO) Head to Head Comparison - Defense World
Sealed Air (SEE) to Release Earnings on Thursday - Defense World
Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 5.2% in July - Defense World
Fecal Microbiota Transplantation Market – 37% of Growth to Originate from APAC -Rebiotix, Finch Therapeutics, Seres Ther – KnowCasino - KnowCasino
American International Group Inc. Decreases Stake in Prosperity Bancshares, Inc. (NYSE:PB) - American Banking and Market News
Human Microbiome Market Size to Surge to US$ 2,884.5 Mn in Recording At A CAGR of 24.6% from 2024-2031 | - WhaTech
Par Pacific (NYSE:PARR) & Vermilion Energy (NYSE:VET) Critical Survey - Defense World
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) & Finch Therapeutics Group (NASDAQ:FNCH) - Defense World
SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight - PR Newswire UK
North African Entrepreneur Amine Finch is Shaking Up the ADHD Space - Yahoo Finance
Page 885 of 2136 - Venture Capital Journal
Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to Buy by Argus - American Banking and Market News
Suburban Propane Partners, L.P. (NYSE:SPH) Shares Sold by Wealth Enhancement Advisory Services LLC - American Banking and Market News
Finch Therapeutics Group Inc Azioni (FNCH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Capitalizzazione:
|
Volume (24 ore):